Hypomethylating Agent Therapy for AML and MDS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) have limited effectiveness, particularly in elderly patients and those with specific genetic mutations, leading to high relapse rates and poor prognosis.
Innovation Solution
The use of hypomethylating agents like 5-azacytidine or decitabine, optionally combined with other therapeutic agents, is administered based on specific gene mutation profiles, such as NPM1, FLT3, DNMT3A, TP53, and IDH2 mutations, to target abnormal cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy treatments are used for AML and MDS, then initial remission can be achieved, but relapse rates are high and overall survival is limited
Solution Approach 1:
The patent performs gene mutation profiling (NPM1, FLT3, DNMT3A, TP53, IDH2) before treatment to identify patients who will respond to hypomethylating agents. This preliminary characterization allows selection of appropriate therapy before treatment begins, preventing wasted time on ineffective conventional chemotherapy and enabling early intervention with the correct agent to maintain remission and extend survival.
Solution Approach 2:
The patent changes the treatment parameter from conventional chemotherapy to hypomethylating agents based on specific gene mutation profiles. This parameter change (therapy selection based on molecular characteristics) transforms the treatment approach, leading to improved remission maintenance and extended overall survival in genetically selected patient populations.
2Duration of action of moving object
If hypomethylating agents are used based on gene mutation profiles, then relapse-free survival is prolonged, but treatment requires precise genetic characterization
Solution Approach 1:
The patent performs comprehensive gene mutation profiling (NPM1, FLT3, DNMT3A, TP53, IDH2) as a preliminary step before initiating hypomethylating agent treatment. This advance genetic characterization enables accurate patient stratification and ensures that only appropriate candidates receive the therapy, maximizing relapse-free survival while managing the complexity of genetic testing through structured protocols.
3Reliability
If conventional treatments are administered without genetic stratification, then treatment protocol is simple, but effectiveness is limited in elderly patients and those with specific mutations
Solution Approach 1:
The patent changes the treatment parameter from uniform conventional chemotherapy to genetically-guided hypomethylating agent therapy. This parameter change based on molecular characteristics (NPM1, FLT3, DNMT3A, TP53, IDH2 mutation status) dramatically improves treatment effectiveness in elderly patients and those with specific mutations, accepting increased protocol complexity as necessary for precision medicine.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more effective treatment strategy by prolonging overall survival and relapse-free survival in patients with specific genetic mutations, improving outcomes for AML and MDS patients.
Implementation Method 1
Methods for using a hypomethylating agent (e.g., 5-azacytidine or decitabine)... to treat diseases and disorders including cancers such as but not limited to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)
Data Source
AI summary
Provided herein are methods of using a hypomethylating agent (e.g., 5-azacytidine or decitabine), optionally in combination with one or more additional therapeutic agents or therapies, to treat diseases and disorders including cancers such as but not limited to acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), based on gene mutation profiles of the diseases and disorders.